One‐year clinical and computed tomography follow‐up after implantation of bioresorbable vascular scaffolds in patients with coronary chronic total occlusions
- 25 October 2017
- journal article
- research article
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 92 (3) , 488-496
Abstract
Objectives: To assess the safety and efficacy of everolimus‐eluting bioresorbable scaffolds (BRS) in the treatment of chronic total occlusions (CTO) using noninvasive multislice computed tomography (MSCT) angiography at one‐year follow‐up.Background: Current evidence regarding the safety and efficacy of BRS for the percutaneous treatment of CTO is limited.Methods: Between September 2013 and January 2016, patients who received one or more ABSORB BRSs were included at three centers. MSCT (including quantitative analysis) and clinical follow‐up were performed at one year.Results: Forty‐one CTO patients were included. Mean age was 60 ± 11 years and the majority was male (83%). Average Japanese CTO (J‐CTO) score was 0.9 ± 0.9. Seventy‐one BRS were implanted in total with, on average, 1.7 ± 0.8 scaffolds/patient, and a total length of 43 ± 20 mm and diameter of 3.1 ± 0.4 mm. One noncardiac death took place. MSCT angiography was performed in 34 (83%) patients: all scaffolds were patent, except in one patient, in whom a patent target vessel was present on subsequent diagnostic angiography. MSCT quality was sufficient for quantitative analyses in 27 patients (46 scaffolds): median reference versus scaffold minimal lumen diameter and minimal lumen area were measured, and showed a small difference of 0.1 mm (−0.2–0.4) (lumen diameter stenosis = 3.0%) and 0.5 mm2 (−1.0–2.0) (lumen area stenosis = 4.2%).Conclusions: The low number of events and high patency rate at 1 year are encouraging the further use of the ABSORB scaffold for CTOs with low J‐CTO score. Noninvasive MSCT angiography is a valid tool to assess scaffold patency, although its image resolution limits the use for quantitative measurements.Keywords
Funding Information
- Abbott Vascular
- Abbott Fund (None)
This publication has 32 references indexed in Scilit:
- A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trialThe Lancet, 2015
- Extended follow-up following “full-metal jacket” percutaneous coronary interventions with drug-eluting stentsCatheterization and Cardiovascular Interventions, 2014
- Bioresorbable scaffolds: rationale, current status, challenges, and futureEuropean Heart Journal, 2013
- Five-Year Clinical and Functional Multislice Computed Tomography Angiographic Results After Coronary Implantation of the Fully Resorbable Polymeric Everolimus-Eluting Scaffold in Patients With De Novo Coronary Artery DiseaseJACC: Cardiovascular Interventions, 2013
- First Serial Assessment at 6 Months and 2 Years of the Second Generation of Absorb Everolimus-Eluting Bioresorbable Vascular ScaffoldCirculation: Cardiovascular Interventions, 2012
- Bioresorbable ScaffoldCirculation, 2011
- Predicting Successful Guidewire Crossing Through Chronic Total Occlusion of Native Coronary Lesions Within 30 MinutesJACC: Cardiovascular Interventions, 2011
- A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methodsThe Lancet, 2009
- Clinical End Points in Coronary Stent TrialsCirculation, 2007
- Trends in Outcomes After Percutaneous Coronary Intervention for Chronic Total OcclusionsJACC, 2007